Brokerages expect Antares Pharma, Inc. (NASDAQ:ATRS) to report ($0.03) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Antares Pharma’s earnings. The highest EPS estimate is ($0.01) and the lowest is ($0.04). Antares Pharma also reported earnings of ($0.03) per share during the same quarter last year. The company is expected to report its next quarterly earnings report on Tuesday, March 13th.

On average, analysts expect that Antares Pharma will report full year earnings of ($0.11) per share for the current financial year, with EPS estimates ranging from ($0.12) to ($0.10). For the next year, analysts expect that the business will post earnings of $0.00 per share, with EPS estimates ranging from ($0.11) to $0.18. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Antares Pharma.

Antares Pharma (NASDAQ:ATRS) last posted its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.03). Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The company had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.01 million. The company’s quarterly revenue was up 11.9% compared to the same quarter last year.

A number of brokerages have recently weighed in on ATRS. HC Wainwright set a $5.00 price objective on Antares Pharma and gave the company a “buy” rating in a research note on Friday, October 13th. ValuEngine cut Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. BidaskClub raised Antares Pharma from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. Finally, Piper Jaffray Companies set a $3.00 price objective on Antares Pharma and gave the company a “buy” rating in a research note on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Antares Pharma has a consensus rating of “Buy” and a consensus target price of $3.84.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Capital Advantage Inc. acquired a new position in Antares Pharma during the 3rd quarter worth $110,000. Alliancebernstein L.P. acquired a new position in Antares Pharma during the 2nd quarter worth $119,000. Legal & General Group Plc acquired a new position in Antares Pharma during the 2nd quarter worth $120,000. MML Investors Services LLC grew its stake in Antares Pharma by 228.2% during the 2nd quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 30,000 shares in the last quarter. Finally, First Eagle Investment Management LLC grew its stake in Antares Pharma by 150.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 50,000 shares of the specialty pharmaceutical company’s stock worth $162,000 after purchasing an additional 30,000 shares in the last quarter. 34.63% of the stock is owned by institutional investors and hedge funds.

Shares of Antares Pharma (NASDAQ:ATRS) traded up $0.05 during midday trading on Thursday, hitting $2.25. The stock had a trading volume of 707,328 shares, compared to its average volume of 853,414. Antares Pharma has a twelve month low of $1.58 and a twelve month high of $4.09. The company has a debt-to-equity ratio of 0.69, a current ratio of 3.34 and a quick ratio of 2.89. The firm has a market capitalization of $352.52, a PE ratio of -20.45 and a beta of 0.25.

TRADEMARK VIOLATION NOTICE: This story was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://theolympiareport.com/2018/01/21/0-03-earnings-per-share-expected-for-antares-pharma-inc-atrs-this-quarter.html.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.